You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

254 Results
Document
Nov 2019
Guidelines and Advice
Status: Current
ID: pet 2019-1
Version: N/A
Nov 2019
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
lenvatinib (Unfunded),
everolimus (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2019
Document
Jan 2020
Document
Mar 2020
Document
May 2020
Guidelines and Advice
Status: Current
ID: PET 2019-2
Version: N/A
Jun 2020
Regimen
Cancer Type:
Gynecologic, 
Ovary
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    niraparib - For the maintenance treatment of newly diagnosed or recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niraparib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Cetuximab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
encorafenib,
cetuximab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Guidelines and Advice
Status: Current
ID: PET 2020-1
Version: N/A
Nov 2020
Guidelines and Advice
Status: Current
Version: 1.0
Dec 2020

Pages